Basic Information
Immunity Pharma Ltd. is a privately held biopharmaceutical company focused on clinical-stage neurology, with an initial emphasis on amyotrophic lateral sclerosis (ALS). IPL's drugs are bioactive peptides capable of stimulating therapeutic cell signaling processes and delaying the progression of neurodegenerative diseases by inducing survival-supporting processes within cells. IPL's drugs are under development for the treatment of ALS, Parkinson's disease, and other neurodegenerative disorders.